GSK’s (GSK) Buy Rating Reiterated at Shore Capital

Shore Capital restated their buy rating on shares of GSK (LON:GSK) in a report released on Thursday, MarketBeat Ratings reports.

A number of other analysts have also recently commented on GSK. Deutsche Bank Aktiengesellschaft restated a buy rating and issued a GBX 1,950 ($24.74) price objective on shares of GSK in a research report on Tuesday, June 18th. Barclays restated an equal weight rating and issued a GBX 1,725 ($21.88) price target on shares of GSK in a report on Tuesday, May 7th. JPMorgan Chase & Co. reiterated an underweight rating on shares of GSK in a report on Tuesday, June 18th. Jefferies Financial Group reissued a buy rating and set a GBX 2,100 ($26.64) target price on shares of GSK in a research note on Thursday. Finally, Citigroup restated a buy rating and set a GBX 2,100 ($26.64) target price on shares of GSK in a report on Monday, June 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of GBX 1,791.25 ($22.72).

GSK Trading Up 0.2 %

LON:GSK opened at GBX 1,529.50 ($19.40) on Thursday. The firm has a market capitalization of £62.40 billion, a price-to-earnings ratio of 1,403.21, a PEG ratio of 1.19 and a beta of 0.27. GSK has a 1-year low of GBX 1,302.60 ($16.52) and a 1-year high of GBX 1,823.50 ($23.13). The business’s 50-day moving average price is GBX 1,685.84 and its two-hundred day moving average price is GBX 1,632.29. The company has a current ratio of 0.87, a quick ratio of 0.73 and a debt-to-equity ratio of 134.34.

GSK Cuts Dividend

The firm also recently announced a dividend, which will be paid on Thursday, July 11th. Stockholders of record on Thursday, May 16th will be given a GBX 15 ($0.19) dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a dividend yield of 0.9%. GSK’s payout ratio is presently 5,504.59%.

Insider Transactions at GSK

In related news, insider Wendy Becker bought 446 shares of the business’s stock in a transaction dated Thursday, June 20th. The stock was purchased at an average cost of GBX 1,614 ($20.47) per share, for a total transaction of £7,198.44 ($9,131.60). Insiders own 1.60% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.